Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published in 2020 – Ann Oncol (2020)
Authors: B. Eichhorst, T. Robak, E. Montserrat, P. Ghia, C. U. Niemann, A. P. Kater, M. Gregor, F. Cymbalista, C. Buske, P. Hillmen, M. Hallek & U. Mey, on behalf of the ESMO Guidelines Committee
- These updated ESMO Clinical Practice Guidelines provide key recommendations on the management of chronic lymphocytic leukaemia (CLL)
- Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe
- Recommendations are provided, including levels of evidence and grades of recommendation where applicable
- Prognosis and treatment decisions in CLL depend on genetic and clinical factors including age, stage and comorbidities
- Therapies targeting B-cell-receptor pathway or defect mechanism of apoptosis induce long lasting remissions
These Clinical Practice Guidelines are endorsed by the European Hematology Association (EHA)